

**DR5 Antibody**  
Catalog # ASC10040**Specification****DR5 Antibody - Product Information**

Application	WB, ICC, IF
Primary Accession	<a href="#">O14763</a>
Other Accession	<a href="#">AF012535</a> , <a href="#">2338419</a>
Reactivity	Human, Mouse
Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Application Notes	DR5 antibody can be used for detection of DR5 expression by Western blot at 2 µg/mL. Antibody can also be used for immunocytochemistry starting at 5 µg/mL. For immunofluorescence start at 10 µg/mL.

**DR5 Antibody - Additional Information**

Gene ID 8795

**Other Names**

DR5 Antibody: DR5, CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLER/DR5, DR5, UNQ160/PRO186, Tumor necrosis factor receptor superfamily member 10B, Death receptor 5, TRAIL receptor 2, tumor necrosis factor receptor superfamily, member 10b

**Target/Specificity**

TNFRSF10B; Antibody has no cross reaction to DR4.

**Reconstitution & Storage**

Antibody can be stored at 4°C up to one year. Antibodies should not be exposed to prolonged high temperatures.

**Precautions**

DR5 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

**DR5 Antibody - Protein Information**

Name TNFRSF10B

Synonyms DR5, KILLER, TRAILR2, TRICK2, ZTNFR9

**Function**

Receptor for the cytotoxic ligand TNFSF10/TRAIL (PubMed:<a href="http://www.uniprot.org/citations/10549288" target="\_blank">10549288</a>). The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the

activation of NF-kappa-B. Essential for ER stress-induced apoptosis.

#### Cellular Location

Membrane; Single-pass type I membrane protein.

#### Tissue Location


Widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines such as HeLaS3, K-562, HL-60, SW480, A-549 and G-361; highly expressed in heart, peripheral blood lymphocytes, liver, pancreas, spleen, thymus, prostate, ovary, uterus, placenta, testis, esophagus, stomach and throughout the intestinal tract; not detectable in brain

#### DR5 Antibody - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


#### DR5 Antibody - Images



Western blot analysis of DR5 in HeLa (H) and K562 (K) cell lysates with DR5 antibody at 2 µg/mL.



Immunocytochemistry of DR5 in HeLa cells with DR5 antibody at 5 µg/mL.



Immunofluorescence of DR5 in HeLa cells with DR5 antibody at 20 µg/mL.

### **DR5 Antibody - Background**

DR5 Antibody: Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family. DR4 was recently identified as the receptor for TRAIL. A novel death domain containing receptor for TRAIL was more recently identified and designated DR5, Apo2, TRAIL-R2, TRICK2, or KILLER by several groups independently. Like DR4, DR5 transcript is widely expressed in normal tissues and in many types of tumor cells. DR5 binds to TRAIL and mediates TRAIL induced cell death. Overexpression of DR5 induces apoptosis and activates NF-κB.

### **DR5 Antibody - References**

Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. *Science* 1997;277:815-8

Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science* 1997;277:818-21

Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. *EMBO J* 1997;16:5386-97

MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. *J Biol Chem* 1997;272:25417-20